Stocks & Investing
Stocks and Investing
Stocks and Investing
Tue, February 9, 2021
[ Tue, Feb 09th 2021
] - WOPRAI
[ Tue, Feb 09th 2021
] - WOPRAI
[ Tue, Feb 09th 2021
] - WOPRAI
[ Tue, Feb 09th 2021
] - WOPRAI
[ Tue, Feb 09th 2021
] - WOPRAI
[ Tue, Feb 09th 2021
] - WOPRAI
[ Tue, Feb 09th 2021
] - WOPRAI
[ Tue, Feb 09th 2021
] - WOPRAI
[ Tue, Feb 09th 2021
] - WOPRAI
[ Tue, Feb 09th 2021
] - WOPRAI
[ Tue, Feb 09th 2021
] - WOPRAI
[ Tue, Feb 09th 2021
] - WOPRAI
[ Tue, Feb 09th 2021
] - WOPRAI
[ Tue, Feb 09th 2021
] - WOPRAI
[ Tue, Feb 09th 2021
] - WOPRAI
[ Tue, Feb 09th 2021
] - WOPRAI
[ Tue, Feb 09th 2021
] - WOPRAI
[ Tue, Feb 09th 2021
] - WOPRAI
[ Tue, Feb 09th 2021
] - WOPRAI
[ Tue, Feb 09th 2021
] - WOPRAI
[ Tue, Feb 09th 2021
] - WOPRAI
[ Tue, Feb 09th 2021
] - WOPRAI
[ Tue, Feb 09th 2021
] - WOPRAI
[ Tue, Feb 09th 2021
] - WOPRAI
[ Tue, Feb 09th 2021
] - WOPRAI
[ Tue, Feb 09th 2021
] - WOPRAI
[ Tue, Feb 09th 2021
] - WOPRAI
[ Tue, Feb 09th 2021
] - WOPRAI
[ Tue, Feb 09th 2021
] - WOPRAI
[ Tue, Feb 09th 2021
] - WOPRAI
Paul Choi Initiated (BBIO) at Strong Buy and Held Target at $83 on, Feb 9th, 2021
Paul Choi of Goldman Sachs, Initiated "BridgeBio Pharma, Inc." (BBIO) at Strong Buy and Held Target at $83 on, Feb 9th, 2021.
Paul has made no other calls on BBIO in the last 4 months.
There are 2 other peers that have a rating on BBIO. Out of the 2 peers that are also analyzing BBIO, 0 agree with Paul's Rating of Hold.
These are the ratings of the 2 analyists that currently disagree with Paul
- Raghuram Selvaraju of "HC Wainwright & Co." Maintained at Strong Buy with Increased Target to $87 on, Monday, January 11th, 2021
- Mani Foroohar of "SVB Leerink" Maintained at Buy with Increased Target to $44 on, Friday, December 4th, 2020
